Krishna Chatterjee

发表

The UK10K project identifies rare variants in health and disease

Tom R. Gaunt, Hashem A. Shihab, Gail P. Clement, 2016 .

Combined point of care SARS-CoV-2 nucleic acid and antibody testing in suspected moderate to severe COVID-19 disease

Steven F. Baker, Kenneth G. C. Smith, J. Briggs, 2020 .

In vitro micronucleus assay –increase in binucleated cells in mononucleate assay

S. Dertinger, M. Cooke, A. Lynch, 2010 .

Loss of function variant in SMIM1 is associated with reduced energy expenditure and weight gain

William J. Astle, Nicholas S. Gleadall, H. Ullum, 2022 .

Steroid receptor coactivator-1 modulates the function of Pomc neurons and energy homeostasis

Tom R. Gaunt, Thomas M. Keane, Hashem A. Shihab, 2019, Nature Communications.

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

J. Haughney, V. Libri, G. Screaton, 2022, Journal of Infection.

No metabolic effects of mustard allyl-isothiocyanate compared with placebo in men

P. Murgatroyd, M. Langeveld, A. Vidal-Puig, 2017, The American journal of clinical nutrition.

Brief Report Combined point of care SARS-CoV-2 nucleic acid and antibody testing in suspected moderate to severe COVID-19 disease.

Steven F. Baker, Nikos, Myra, 2020 .

Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant

Steven F. Baker, Kenneth G. C. Smith, N. Walker, 2020, Cell Reports Medicine.

Improved imputation of low-frequency and rare variants using the UK10K haplotype reference panel

Tom R. Gaunt, Klaudia Walter, Nicholas J Timpson, 2015, Nature Communications.

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Scott M Elliott, J. Haughney, V. Libri, 2021, The Lancet.

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

J. Haughney, V. Libri, M. Kamal, 2022, The Lancet Infectious Diseases.

Quantifying energy expenditure in childhood: utility in managing pediatric metabolic disorders

P. Murgatroyd, C. Acerini, M. Venables, 2019, The American journal of clinical nutrition.

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial

J. Haughney, V. Libri, J. Nguyen-Van-Tam, 2023, Journal of Infection.

Clinical Consequences of Variable Results in the Measurement of Free Thyroid Hormones: Unusual Presentation of a Family with a Novel Variant in the THRB Gene Causing Resistance to Thyroid Hormone Syndrome

S. Cannavò, L. Persani, L. Fugazzola, 2021, European Thyroid Journal.

Abstracts of the 33 rd Annual Meeting of the United Kingdom Environmental Mutagen Society, 12 th - 14 th July 2010 at the University of Derby, UK. Photo geno toxicity – science without application?

S. Dertinger, M. Cooke, A. Lynch, 2010 .

Improved imputation of low-frequency and rare variants using the UK10K haplotype reference panel

Tom R. Gaunt, Thomas M. Keane, Hashem A. Shihab, 2015, Nature Communications.